您所在的位置: 品牌專(zhuān)欄
奧拉帕利聯(lián)合度伐利尤單抗治療卵巢癌的臨床效果
2024-03-22
標簽:
其他
  
瀏覽量:8847
本期精選3篇婦產(chǎn)科相關(guān)領(lǐng)域文章,對摘要進(jìn)行了翻譯,與婦產(chǎn)科同仁共讀: 1.Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Na?ve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study 奧拉帕利聯(lián)合度伐利尤單抗作為PARP抑制劑初治鉑敏感復發(fā)性卵巢癌患者的治療:一項II期多隊列研究 2.Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes. 動(dòng)態(tài)血糖監測指標與糖尿病患者妊娠結局的關(guān)聯(lián) 3.Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. 貝伐珠單抗聯(lián)合化療,同時(shí)加用阿替利珠單抗治療轉移性、持續性或復發(fā)性宮頸癌的3期臨床試驗

評論(0)
精彩評論